Breast cancer
RecruitingStudy of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease
Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease
- Disease:Breast cancer
- Substances:CapecitabineCarboplatin+5
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting










